NCT04278248View on ClinicalTrials.gov

Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above

PHASE3CompletedINTERVENTIONAL

Enrollment

1,940

Participants

Timeline

Start Date

January 12, 2018

Primary Completion Date

June 7, 2018

Study Completion Date

June 7, 2018

Conditions

Pneumonia, Pneumococcal

Interventions

BIOLOGICAL

23-Valent Pneumococcal Polysaccharide Vaccine

1 dose according to age of subjects. Single intramuscular dose contains 0.5ml 23-Valent Pneumococcal Polysaccharide Vaccine.

Trial Locations (1)

530028

Yizhou Center for Disease Control and Prevention, Yizhou

All Listed Sponsors

lead

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

INDUSTRY

NCT04278248 - Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above | Biotech Hunter | Biotech Hunter